In order to test if Lyn controls ROR1 trafficking or endocytosis to reduce ROR1 surface dynamics and to control chemotaxis, we analyzed the response of CLL cells to the Lyn inhibitor Dasatinib (25 nM). Here, LYN is linked to B-cell chronic lymphocytic leukemia.